



The TIMI Trials

MERLIN-TIMI 36

OBJECTIVE: To evaluate a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes.

1. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E for the MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST elevation acute coronary syndromes (MERLIN) – TIMI 36 trial. *Am Heart J* 2006;151:1186e1-9.
2. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. *JAMA* 2007;297:1775-83.
3. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FWA, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. *Circulation* 2007;116:1647-52.
4. Bonaca MP, Scirica BM, Sabatine MS, Dalby A, Spinar J, Melanson S, Jarolim P, Morrow DA. Prospective evaluation of the prognostic implications of low level elevation of cardiac troponin using a new highly-sensitive assay for cardiac troponin I: results from the MERLIN-TIMI 36 trial. *Circulation* 2007; 116(16 Suppl II):II-381.
5. Mega JL, Hochman JS, Scirica BM, Murphy SA, McCabe CH, Merlino P, Niguarda O, Morrow DA. . Anti-ischemic effects of ranolazine in women: results from the randomized, placebo-controlled MERLIN-TIMI 36 trial. *Circulation* 2007; 116(16 Suppl II):II-538.
6. Arnold SV, Morrow DA, Wang K, Lei Y, Mahoney EM, Kempf JA, Scirica BM, Cohen DJ. Effects of ranolazine on disease-specific health status and quality of life: results from the MERLIN-TIMI 36 Randomized Trial. *J Am Coll Cardiol* 2008;51:A215.
7. Scirica BM, Sabatine MS, Jarolim P, Sloan S, Murphy SA, de Lemos JL, Morrow DA. Myeloperoxidase levels associated with risk of cardiovascular death and heart failure after non-ST elevation acute coronary syndrome. *J Am Coll Cardiol* 2008;51:A218.
8. Mega JL, Scirica BM, Qin J, Gibson CM, Morrow DA. Chronic kidney disease, cardiovascular outcomes, and treatment disparities following non-ST elevation myocardial infarction. *J Am Coll Cardiol* 2008;51:A220.
9. Wilson SR, Morrow DA, Scirica BM, Murphy SA, Buros JL, McCabe CH, Braunwald E. Efficacy and safety of ranolazine in chronic angina: observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI 36 trial. *J Am Coll Cardiol* 2008;51:A225.